Martyn A. Sharpe

Martyn A. Sharpe, PhD

John S. "Steve" Dunn, Jr. Distinguished Professorship in Brain Tumor Research, Department of Neurosurgery
Research Professor of Neurosurgery, Academic Institute
Associate Research Member, Research Institute
Houston Methodist


Baskin Lab


masharpe@houstonmethodist.org
Biography

Martyn A. Sharpe is a classically trained biochemist and bioenergeticist with a strong background in chemistry and the reactions of both reactive oxygen and nitrogen species. He has had more than a decade’s worth of experience in examining the cell proliferation/death mechanisms, and has examined the growth and characteristics of many different cell types including astrocytes, neurons and neuronal/astrocyte co-cultures.

Dr. Sharpe enjoys a large number of collaborations/friendships with scientists worldwide and has published papers with 85 co-authors over the last 15 years. He is often asked to participate in projects where there is an overlap of chemistry/cell physiology; especially in the areas of reactive oxygen/nitrogen species.

Dr. Sharpe switched from classical biochemistry/bioenergetics into related pathologies, especially of the brain, a decade ago following the death of his uncle from glioblastoma multiforme, soon after diagnosis. He has used the knowledge he acquired to develop drugs and drug delivery systems to target gliomas.
In addition to nanosyringes Sharpe & Baskin have been developing prodrugs to target gliomas that are based on their maturation by monoamine oxidase B (MAOB).

Martyn is deeply committed to neuro-oncology and is determined to develop a therapy to treat the 220,000 people, worldwide, who develop gliomas each year.

Description of Research

Dr Sharpe main areas of research have been the following:
-Design, synthesis and testing in vitro and in vivo MAOB activated pro-drugs and retention dyes for the treatment of glioma.
-Development of targeted nanosyringes for chemotherapy
-Examination of the sensitivity of human brain cells, astrocytes and neuron’s, toward organomercury
-Development of assays for identifying specific lesions in DNA

Areas Of Expertise

Nanotechnology Drug design
Publications

Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas
Ijare, OB, Hambarde, S, Brasil Da Costa, FH, Lopez, S, Sharpe, MA, Helekar, SA, Hangel, G, Bogner, W, Widhalm, G, Bachoo, RM, Baskin, DS & Pichumani, K 2022, , Neuro-oncology, vol. 24, no. 4, pp. 556-568. https://doi.org/10.1093/neuonc/noab219

Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells
Sharpe, MA, Baskin, DS, Pichumani, K, Ijare, OB & Helekar, SA 2021, , Frontiers in Oncology, vol. 11, 768758. https://doi.org/10.3389/fonc.2021.768758

Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells
Sharpe, MA, Baskin, DS, Pichumani, K, Ijare, OB & Helekar, SA 2021, , Frontiers in Oncology, vol. 11, 768758. https://doi.org/10.3389/fonc.2021.768758

Hijacking sexual immuno-privilege in GBM-an immuno-evasion strategy
Sharpe, MA, Baskin, DS, Jenson, AV & Baskin, AM 2021, , International journal of molecular sciences, vol. 22, no. 20, 10983. https://doi.org/10.3390/ijms222010983

METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT
Helekar, SA, Baskin, DS, Sharpe, MA & Pichumani, K Sep. 22 2021, , Patent No. EP3880299.

Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas
Ijare, OB, Hambarde, S, Brasil Da Costa, FH, Lopez, S, Sharpe, MA, Helekar, SA, Hangel, G, Bogner, W, Widhalm, G, Bachoo, RM, Baskin, DS & Pichumani, K 2021, , Neuro-oncology, vol. 24, no. 4, https://doi.org/10.1093/neuonc/noab219, pp. 1-13. https://doi.org/10.1093/neuonc/noab219

Regulation | Monoamine oxidases
Raghavan, S, Baskin, DS & Sharpe, MA 2021, . in Encyclopedia of Biological Chemistry: Third Edition. vol. 1, Elsevier, pp. 542-560. https://doi.org/10.1016/B978-0-12-819460-7.00343-1

Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device
Baskin, DS, Sharpe, MA, Nguyen, L & Helekar, SA 2021, , Frontiers in Oncology, vol. 11, 708017. https://doi.org/10.3389/fonc.2021.708017

The leloir cycle in glioblastoma: Galactose scavenging and metabolic remodeling
Sharpe, MA, Ijare, OB, Baskin, DS, Baskin, AM, Baskin, BN & Pichumani, K 2021, , Cancers, vol. 13, no. 8, 1815. https://doi.org/10.3390/cancers13081815

Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields
Helekar, SA, Hambarde, S, Ijare, OB, Pichumani, K, Baskin, DS & Sharpe, MA 2021, , Journal of Cancer Research and Clinical Oncology, vol. 147, no. 12, pp. 3577-3589. https://doi.org/10.1007/s00432-021-03787-0

Elevated levels of circulating betahydroxybutyrate in pituitary tumor patients may differentiate prolactinomas from other immunohistochemical subtypes
Ijare, OB, Holan, C, Hebert, J, Sharpe, MA, Baskin, DS & Pichumani, K 2020, , Scientific Reports, vol. 10, no. 1, 1334. https://doi.org/10.1038/s41598-020-58244-8

MP-Pt(IV): A MAOB-sensitive mitochondrial-specific prodrug for treating glioblastoma
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Molecular Cancer Therapeutics, vol. 19, no. 12, pp. 2445-2453. https://doi.org/10.1158/1535-7163.MCT-20-0420

MP-Pt(IV): A MAOB-sensitive mitochondrial-specific prodrug for treating glioblastoma
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.MCT-20-0420

A ”clickable” probe for active MGMT in glioblastoma demonstrates two discrete populations of MGMT
Raghavan, S, Baskin, DS & Sharpe, MA 2020, , Cancers, vol. 12, no. 2, 453. https://doi.org/10.3390/cancers12020453

Proton magnetic resonance spectroscopy characterization of Rathke’s cleft cysts (RCCs): Relevance to the differential diagnosis of pituitary adenomas and RCCs
Ijare, OB, Sharpe, MA, Baskin, DS & Pichumani, K 2020, , Cancers, vol. 12, no. 2, 360. https://doi.org/10.3390/cancers12020360

Fibrinogen chains intrinsic to the brain
Golanov, EV, Sharpe, MA, Regnier-Golanov, AS, Del Zoppo, GJ, Baskin, DS & Britz, GW 2019, , Frontiers in Neuroscience, vol. 13, no. MAY, 541. https://doi.org/10.3389/fnins.2019.00541

Metabolism of fructose in B-cells: A 13C NMR spectroscopy based stable isotope tracer study
Ijare, OB, Baskin, DS, Sharpe, MA & Pichumani, K 2018, , Analytical Biochemistry, vol. 552, pp. 110-117. https://doi.org/10.1016/j.ab.2018.04.003

PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma
Sharpe, MA, Raghavan, S & Baskin, DS 2018, , Oncotarget, vol. 9, no. 35, pp. 23923-23943. https://doi.org/10.18632/oncotarget.25246

Transfer of Dyes and Drugs into Cells Using EGFR-Targeted Nanosyringes
Nilewski, LG, Singh, M, Baskin, DS, Tour, JM & Sharpe, MA 2017, , ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.7b00138

Metabolic sculpting of the mitochondria, cell signaling and the cancer phenotype
Sharpe, MA, Ismail, N & Baskin, DS 2017, , Translational Cancer Research, vol. 6, pp. S182-S188. https://doi.org/10.21037/tcr.2017.01.33